Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
(2R,4S)-1-(4-butoxyphenyl)sulfonyl-N-hydroxy-4-(methanesulfonamido)pyrrolidine-2-carboxamide is a synthetic small molecule identified as a potent inhibitor of Matrix Metalloproteinase 3 (MMP3). It belongs to the class of hydroxamate-based MMP inhibitors, which typically function by chelating the catalytic zinc ion in the active site of MMP enzymes. The compound's interaction with MMP3 has been characterized through X-ray diffraction studies, as evidenced by its presence in the Protein Data Bank (PDB entry 1G49) in complex with MMP3. While specific therapeutic indications or development status for this exact compound are not widely detailed in public databases, MMP inhibitors have historically been investigated for various conditions involving tissue remodeling and inflammation, such as arthritis and cancer.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on (2R,4S)-1-(4-butoxyphenyl)sulfonyl-N-hydroxy-4-(methanesulfonamido)pyrrolidine-2-carboxamide.